Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.

Abstract

OBJECTIVES:

The aims of this study were to determine the response rate of pyrazoloacridine (PZA) in patients with recurrent or persistent endometrial carcinoma and to describe the nature and degree of toxicity in this population.

METHODS:

PZA was initially administered at a dose of 750 mg/m(2) intravenously over 3 h every 3 weeks but, due to toxicity, was subsequently reduced to 560 mg/m(2) at the same schedule.

RESULTS:

Among 23 evaluable patients, 11 of whom had had prior chemotherapy, there was 1 (4.3%) partial response and no complete responses. Forty-eight percent of patients had grade 4 neutropenia. There was 1 treatment-related death, in a patient who had prior chemotherapy and radiotherapy.

CONCLUSION:

This dose and schedule of PZA has insignificant activity in this population. The optimal PZA dose appears to vary between different populations and may be related to prior therapy.

• Authors: Steven C Plaxe, John A Blessing, Nader Husseinzadeh, Kenneth D Webster, Janet S Rader, Charles J Dunton
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 84 Issue 2 Pg. 241-4 (Feb 2002) ISSN: 0090-8258 [Print] United States
• PMID: 11812081 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)
• Copyright: ©2001 Elsevier Science.

Chemical References

• Acridines
• Antineoplastic Agents
• Pyrazoles
• NSC 366140

Topics

• Acridines (adverse effects, therapeutic use)
• Aged
• Aged, 80 and over
• Antineoplastic Agents (adverse effects, therapeutic use)
• Drug Administration Schedule
• Endometrial Neoplasms (drug therapy)
• Female
• Humans
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Pyrazoles (adverse effects, therapeutic use)